Physician profile
Thomas S Potter
NPI 1417052283
$5,838.92
in general payments reported to CMS, 2019-2025
19 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $101 · 2021: $372 · 2022: $746 · 2023: $1,040 · 2024: $1,619 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,188 · Education: $24.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,188.09 |
| Education | $24.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,178.40 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $730.33 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $722.05 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $612.01 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $602.82 | 2019-2025 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $475.20 | 2019-2024 | |
| Genzyme Corporation | $462.66 | 2021-2025 | |
| Galderma Laboratories, L.P. | $223.68 | 2023-2025 | Nemluvio |
| Pfizer INC. | $177.93 | 2023-2024 | |
| Leo Pharma INC. | $173.51 | 2024-2025 | Adbry, Anzupgo |
| Organon LLC | $130.54 | 2025 | Vtama |
| Ucb, INC. | $79.67 | 2019-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $69.93 | 2024-2025 | Zoryve |
| Dermira, INC. | $59.50 | 2019-2020 | |
| Amgen INC. | $56.65 | 2023-2024 | Otezla |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $24.11 | 2021 | |
| Dermavant Sciences, INC. | $21.83 | 2024 | Vtama |
| Incyte Corporation | $19.50 | 2022 | |
| Celgene Corporation | $18.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.